KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Gains from Sales and Divestitures (2023 - 2025)

Historic Gains from Sales and Divestitures for Globus Medical (GMED) over the last 3 years, with Q3 2025 value amounting to $117000.0.

  • Globus Medical's Gains from Sales and Divestitures fell 6685.55% to $117000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $117000.0, marking a year-over-year decrease of 6685.55%. This contributed to the annual value of $367000.0 for FY2024, which is 2306.08% down from last year.
  • According to the latest figures from Q3 2025, Globus Medical's Gains from Sales and Divestitures is $117000.0, which was down 6685.55% from $114000.0 recorded in Q2 2025.
  • Over the past 5 years, Globus Medical's Gains from Sales and Divestitures peaked at $477000.0 during Q4 2023, and registered a low of $98000.0 during Q1 2025.
  • For the 3-year period, Globus Medical's Gains from Sales and Divestitures averaged around $284666.7, with its median value being $304000.0 (2024).
  • In the last 5 years, Globus Medical's Gains from Sales and Divestitures tumbled by 1828.7% in 2024 and then tumbled by 6733.33% in 2025.
  • Globus Medical's Gains from Sales and Divestitures (Quarter) stood at $477000.0 in 2023, then dropped by 23.06% to $367000.0 in 2024, then crashed by 68.12% to $117000.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $117000.0 for Q3 2025, versus $114000.0 for Q2 2025 and $98000.0 for Q1 2025.